



State of Louisiana
Department of Health and Hospitals
Immunization Program

DATE: May 18, 2010
TO: Vaccines for Children Providers
FROM: Rubén A Tapia, MPH, Director
Immunization Program

A handwritten signature in black ink, appearing to read "Rubén A Tapia".

Patricia Simon 
Vaccines Procurement and Distribution Manager

Please route to:

- Clinical supervisor
- Medical director
- Clinic manager
- Clinic staff
- Pharmacy
- Vaccine staff

Subject: Rotarix reinstatement

As you know, in March the FDA made the recommendation to temporarily suspend the use of Rotarix (GSK Rota, NDC 58160-0805-11). Last week, FDA announced revised recommendations for rotavirus vaccines. FDA has determined that it is appropriate for health care providers to resume the use of GSK Rotarix, and to continue the use of Merck RotaTeq: "The agency reached its decision based on a careful evaluation of information from laboratory results from the manufacturers and the FDA's own laboratories, a thorough review of the scientific literature, and input from scientific and public health experts, including members of the FDA's Vaccines and Related Biological Products Advisory Committee that convened on May 7, 2010 to discuss these vaccines."

The official FDA release can be viewed in its entirety at:
<http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm212149.htm>

Inquiries may be directed to the Immunization Program at 504-838-5300. The Immunization Program appreciates your part in distributing, and making this memo available to your staff. This Memorandum should be kept for future reference.

Thank you!